Method for selecting patients with ischemic heart disease and combined pathology and diabetes for additional prescription of laser therapy

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to cardiology and laser therapy, and may be used in treating the patients with ischemic heart disease (IHD) or patients with IHD combined with diabetes. A method involves standard therapeutic treatment of the disease. Before the beginning of treatment, blood glucose and total blood cholesterol are evaluated. If blood glucose in the patients with IHD is less than 4.75 mmol/l and total blood cholesterol in the patients with IHD combined with diabetes is less than 5.5 mmol/l, laser therapy is additionally prescribed.

EFFECT: method provides proved prescription of an additional type of treatment in the form of laser therapy due to prediction of its efficacy on the basis of simple objective criteria without using expensive examination in the patients.

1 tbl

 

The invention relates to medicine, particularly cardiology and therapy, and can be used for selection of patients with coronary heart disease in combination with diabetes for more destination therapy with high treatment efficiency.

Laser therapy registered by the Ministry of health and approved for use in the Russian Federation. There is a clear scheme of combination therapy with medical therapy, according to which is best therapeutic effect. Laser therapy is effective and shown to function in diseases of the cardiovascular system, in particular for coronary heart disease (CHD).

In the prior art it is known a large number of studies demonstrating good effects of laser therapy. In the publication "blood Lipid profile, lipid peroxidation and antioxidant protection in patients with ischemic heart disease with chronic heart failure on background therapy" (found in the Internet www.belmapo.by/downloads/.../2009/lipidnij_spektor_krovi.doc the authors Baida A.V. and others) indicated that the use of laser therapy helps normalize lipid spectrum of blood, HALF-AOD, which indicates the feasibility of inclusion in the complex therapy of patients with coronary artery disease therapy.

In the publication "Laser therapy ish the economic heart disease" (found http://riktamed.ru/php/content.php?id=13268, author Barsukova T.U.) the data of a comparative study of traditional medical and supplemented by laser therapy treatments for coronary heart disease. Clearly presents the advantage of laser therapy compared with medical.

However, in clinical practice it is known that not all patients received in addition to the traditional course of laser therapy, a positive effect is the same. Meets and intolerance of laser radiation in the form of allergic skin reactions, and lack of treatment effect with the additional use of laser therapy.

The question of predicting the degree of effectiveness of the assignment of a course of laser therapy is devoted to a number of eligible methods.

There is a METHOD of EVALUATING the EFFECTIVENESS of LASER therapy (U.S. Pat. No. 94035531 (RU) from 27.08.1996). The authors conduct blood sampling before and after laser therapy, the impact on data and a control sample of blood hemolytica and determining the change in optical density before and after treatment. On blood samples before exposure hemolyticum spend their incubation with lectins in doses priporogovoi concentration does not cause agglutination of red blood cells, and judge the results on the dynamics of the distribution of erythrocytes by resistance in the following way: when the number of value-resistant red blood cells after laser therapy at the Aulnay with initially reduced their number in comparison with the control treatment is effective. When the number decreased-resistant erythrocytes of patients after therapy with initially reduced their number shows the extension of the course of laser therapy. When reducing the number of erythrocytes laser therapy is not effective.

The disadvantages of the method: the method is time-consuming, requires the use of additional laboratory equipment, time.

There is a METHOD of EVALUATING the EFFECTIVENESS of COMBINED MEDICATION LASER TREATMENT (U.S. Pat. No. 2208461 (RU) from 20.07.2003). The method provides the objectification and standardization of the evaluation of the effectiveness of combined medication laser treatment. Examine the liquid crystal structure in the model system with L-lecithin, 10% albumin in 0.9% sodium chloride and native environments of an organism after exposure to low-intensity laser, and with the addition of the drug and in cases of their synergistic effects on the liquid crystal structure and the native environment of an organism recommend concomitant use.

The disadvantages of the method: the method is time-consuming, requires the use of additional laboratory equipment, time, qualified personnel.

The known METHOD of MONITORING the CONDITION of PATIENTS with ISCHEMIC HEART DISEASE DURING TREATMENT ENDOVENOUS LASER THERAPY (U.S. Pat. No. 2127881 from 20.03.1999).

SPO is about intended to diagnose heart disease and rapid monitoring the effectiveness of treatment of coronary heart disease (CHD) intravenous low-intensity laser therapy including background drug treatment according to the standard scheme. Determine the chemiluminescence (CHL) undiluted whole blood in the dynamics before treatment and during treatment. The kinetics of CHL register in the presence of only lyuminola or another fluorescent probe without activators oxidative burst of neutrophils, which allows to drastically simplify the procedure for preparation of the samples. When this fluorescent probe is added to undiluted whole blood at concentrations of 10-5 - 10-3 M Method first allows you to quickly and quantitatively to determine the need for continuing treatment of patients with ischemic heart disease low-intensity laser therapy.

There is a METHOD of DETERMINING sensitivity of INDIVIDUAL PATIENTS with ISCHEMIC HEART DISEASE LASER THERAPY (U.S. Pat. No. 2031408 (RU) from 20.03.1995).

Patients to intravenous irradiation of blood helium-neon laser and later, 1 hour after the session in plasma determine the level of malonic dialdehyde and a quick flash of chemiluminescence, when the decline after the first session regarding the control predict individual sensitivity of patients to laser therapy, and with increasing values of these indicators is the lack of it. The disadvantages of the method requires additional equipment and time.

There is a METHOD of DETERMINING the SENSITIVITY TO INTRAVENOUS LASER IS the treatment of PATIENTS with ISCHEMIC HEART DISEASE (U.S. Pat. No. 2012885 from 15.05.1994).

Determine the activity of any of lysosomal enzymes in the serum of the patient, the resulting value is compared with a criterion, which is equal to 2K (where K equals to the value of this enzyme activity in healthy people), and when the value of this enzyme activity below 2K predict a positive effect of laser therapy in the patient of the disease, and at the level of enzyme activity above criteria predict the futility of laser therapy for the patient.

The purpose of the invention is to develop a method that allows for objective criteria to prescribe the patient with ischemic heart disease in combination with diabetes mellitus in addition to the basic laser treatment. The method is based on the individual assessment of the level of biochemical parameters at admission, clearly defines the forecast of the possible efficacy or futility of the use of laser therapy for each patient.

The technical result achieved by studying the dynamics of biochemical parameters during treatment with standard therapeutic regimens and with the addition of such schemes laser therapy in patients with coronary artery disease and the combination of this pathology with diabetes.

As a standard therapeutic regimens for patients with ischemic heart disease used (Diagnosis and treatment is of stable angina: Russian guidelines (second revision). - M., 2008. - 40 S.): antiplatelet means, in particular acetylsalicylic acid (Trombo-ass), at a daily dose of 75 to 150 mg; lipid-lowering means - simvastatin (Vasiliy) in a daily dose of from 20 to 40 mg or atorvastatin (Liponorm) from 10 to 20 mg per day; β-blockers - bisoprolol (Concor) from 5 to 10 mg/day or metoprolol (egilok-retard) from 100 to 200 mg/day; blockers slow calcium channels - amlodipine (Amlotop) from 5 to 10 mg/day; ACE inhibitors - enalapril (Enap) from 10 to 20 mg/day or perindopril (Prestarium A) from 5 to 10 mg/day; nitrates - the isosorbide dinitrate treatment (Kardiket-retard) from 40 to 60 mg/day or isosorbide Mononitrate (Monosan) from 40 to 60 mg/day; the products of metabolic steps: Trimetazidine (Preductal MB) in the standard dose of 70 mg/day.

Patients with coronary heart disease in combination with SD as a standard therapeutic regimens used (Algorithms specialized medical care to patients with diabetes mellitus / edited Dev, Mvista.com; Moscow, 2009, 103 pages) hypoglycemic therapy: drugs of the sulfonylurea (PSM) - gliclazide MB 30-90 mg/day or glimepiride 2-6 mg/day; Metformin - 500-1500 mg/day; insulin soluble human genetic engineering - 8-30 IU/day, or isophane insulin human genetically 8-32 IU/day, or insulin detemir - 8-30 IU/day; two-phase insulin aspart - 10-36 IU/day.

Por the drugs were prescribed in the following combinations: PSM + Metformin; PSM + Metformin + insulin (isophane insulin human genetically engineered insulin detemir, biphasic insulin aspart); Metformin + insulin (isophane insulin human genetically engineered insulin detemir, biphasic insulin aspart; Insulin (insulin soluble human genetic engineering + isophane insulin human genetically engineered, biphasic insulin aspart).

For the correction of CHD manifestations used statins 10-20 mg/day; acetylsalicylic acid (ASA) 75-150 mg/day. Antiischemic therapy included selective beta 1 blockers of 2.5 - 10 mg/day; calcium channel blockers (CCBS) dihydropyridine (DHP) long-term actions 40-80 mg/day; ACE inhibitors - 5-20 mg/day.

All analyzed 175 histories of patients treated in clinical departments GOU VPO ugma them. NEA University from 2007 to 2009. Patients recorded the following parameters: type of disease (CHD or CHD in combination with DM); therapeutic scheme (standard therapy or with the additional appointment of laterality); age (number of years); gender. Twice before treatment and during the week after the end of treatment to determine the level of triglycerides in the blood (mmol/l); HDL cholesterol (HDL) in the blood (mmol/l); LDL cholesterol (LDL) in the blood (mmol/l); total choles the Wendy Erin blood (mmol/l); cholesterol haemoglobin rate (used); APTT (sec); international normalized ratio (MPE); prothrombin, % (Quick); prothrombin time (sec.); thrombin time (sec); fibrinogen blood (g/l); glycosylated hemoglobin (HbAlc; %); blood glucose (mmol/l), insulin (DPC, USA, mkme/ml); C-peptide (DPC, USA, ng/ml); total oxidative capacity (TOC); total antioxidant activity; free radical oxidation of LDL; superoxide dismutase (SOD); leptin (ng/ml).

It was further determined the dynamics of each of biochemical parameters by calculating the percentage change of the index after treatment with regards to the value of the index before treatment. Using multiple linear regression to determine the impact on the dynamics of each indicator type of disease, type of treatment, age, gender and level of each of the indicators prior to treatment. For qualitative indicators, such as type of disease, type of treatment, gender, use the following marking. Pathologies: 0 - absent (for the control group of healthy individuals), 1 - CHD 2 CHD in combination with diabetes; treatment - 0 - no treatment (control group of healthy individuals), 1 - standard therapeutic regimen for each pathology; 2 - standarten therapeutic scheme, supplemented by a laser; gender: 0 - female, 1 male. Against the t is specified in the number of full years at the time of the survey.

An example table with the calculation of the influence on the dynamics of triglycerides blood other measured patient data, see below (table 1).

The data in the table demonstrates that therapy statistically significantly affect the dynamics of the level of triglycerides.

Similar calculations were conducted for evaluation of their influence on the dynamics of each of the indicators of treatment in the total array of data, including healthy persons (indicating pathology - 0; therapy - 0), patients with ischemic heart disease, one group was treated with standard therapy, the second using standard therapy with the addition of laterality, patients with ischemic heart disease in combination with DM, also divided into two groups - only standard therapy and standard therapy with the addition of laterality.

In addition, the effectiveness of therapy in the same way additionally evaluated in the two data samples, including healthy individuals and patients with only coronary artery disease and healthy individuals and patients with ischemic heart disease in combination with diabetes.

As a result of calculations established that therapy had no statistically significant influence on the dynamics of indicators such as cholesterol LDL blood, APTT, prothrombin, prothrombin time, blood glucose both in the total array of research and splitting the array into two groups according to the type of pathology. Of particular interest to patients CHD and diabetes are lipoproteins and glucose, was therefore carried out the next stage of the research consists in the calculation of the level for each of these indicators, which will be the threshold. That is the value of glucose levels or LDL cholesterol, while raising or lowering whose appearance was assigned therapy will have a statistically significant influence on the dynamics of this index.

Age
Table 1
Impact on the dynamics of triglycerides blood of a set of indicators
IndexThe coefficient estimatesStandard errorT-statisticsThe coefficient of reliability
Constant2,204581,643011,341790,1819
View pathology-0,1639620,196354-0,8350340,4051
Therapy0,5096570,08179866,230630,0000
0,006176020,006562920,9410470,3483
Floor-0,3714530,49866-0,7449020,4576
Triglycerides blood (mmol/l)0,4645880,1461763,178270,0018
The HDL-cholesterol (HDL) (mmol/l)0,01565050,3081350,0507910,9596
The LDL cholesterol (LDL) (mmol/l)-0,01270850,280331-0,04533370,9639
Total blood cholesterol (mmol/l)-0,1112910,272906-0,4078010,6840
Cholesterol haemoglobin rate (used)-0,04792690,0396838-1,207720,2292
APTT (seconds) -0,02393170,0106899-2,238730,0268
The Intern. normalized ratio (MPE)-1,817490,567542-3,202380,0017
Prothrombin, % (Quick)-0,008240910,00553509-1,488850,1388
Prothrombin time (sec)0,1010940,0494652,043740,0429
Thrombin time (sec)0,02484710,03894230,6380490,5245
Fibrinogen blood (g/l)-0,006265710,0723644-0,08658550,9311
Glycodelin. hemoglobin (HbAlc %)0,1175870,04496012,615360,0099
Glucose (mmol/l)-0,117994 0.0832336-1,417620,1585
Insulin (DPC, USA, mkme/ml)-0,0733290,0405192-1,809730,0725
C-peptide (DPC, USA, ng/ml)-0,06862330,0629738-1,089710,2777
Total oxidative capacity (TOC)-0,06196570,078587-0,7884980,4317
General antiokisliteljnaya activity-0,0009649140,00145034-0,6653010,5070
Free radical oxidation of LDL-0,000794780,00159833-0,4972560,6198
Superoxide dismutase (SOD)-0,2964640,236086-1,255750,2113
Leptin (ng/ml)-0,000691620,0098713 -0,1155180,9082

The calculations showed that in the group of patients only with CHD important is the blood glucose level is the coefficient of the regression equation 0,0477373, the level of significance of the impact indicator 0,0651. The blood glucose level at admission to hospital in patients of this group is greater than the value of 4.75 mmol/l, was associated with the absence of effective dynamics of treatment with supplemental therapy. In patients, the blood glucose level at admission was equal to or above 4.75 mmol/l, with the addition of standard therapeutic schema laserotherapy significantly significantly compared to patients treated with only the standard therapeutic regimens, improved subjective assessment of their health and objective indicators.

In patients with coronary heart disease in combination with diabetes important biochemical indicator in determining the effectiveness of treatment, was the level of total blood cholesterol - coefficient regression equation 0,0633541 the level of significance of the impact indicator 0,0292.

In patients, the levels of total blood cholesterol which at admission to treatment was below 5.5 mmol/l, additional therapy was given good therapeutic effect. Patients with coronary heart disease in combination with sugar Diab is om, the level of blood cholesterol which in admission to treatment was higher than 5.5 mmol/l, with the additional purpose of laser therapy on subjective and objective assessments showed the worst performance of the treatment compared to the group receiving only standard therapy.

Thus, the research identified criteria for the selection of patients with CHD or CHD in combination with diabetes mellitus for the purpose in addition to standard therapy laterality.

It is established that patients with coronary heart disease, the blood glucose level at admission to treatment exceeds the 4.75 mmol/l, in addition to the standard treatment to prescribe the laser therapy is not necessary.

Patients with diabetes mellitus in combination with coronary heart disease, total cholesterol blood which at admission to treatment than 5.5 mmol/l, in addition to the standard treatment to prescribe the laser therapy is not necessary.

The method is easy to use, does not require additional expensive survey and at the same time allows reasonably be assigned as an additional method of treatment with laser therapy.

A method for the treatment of patients with coronary heart disease (CHD) or with a combination of coronary heart disease with diabetes, including standard therapeutic treatment, wherein prior to the treatment opredelyayushee glucose and total cholesterol blood and when the blood glucose in patients with CHD exceeding 4.75 mmol/l and the index of total blood cholesterol in patients with coronary heart disease in combination with diabetes less than 5.5 mmol/l advanced spend the laser therapy.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and biotechnology, and may be used for intensifying the vascular growth in ischemic tissues. An agent under the invention contains the plasmid construct pC4W-hVEGFopt bearing the optimised gene hVEGFopt of vascular endothelial growth factor, and in addition the plasmid construct pC4W-hHGFopt bearing the optimized gene hHGFopt hepatocyte growth factor. The method under the invention consists in the intramuscular introduction of a mixture of the plasmid constructs pC4W-hVEGFopt and pC4W-hHGFopt in 0.9% NaCl in ischemic extremity.

EFFECT: use of inventions allows providing effective angiogenesis in ischemic tissue.

4 cl, 1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: solid dosage form contains valsartan, amlodipine, hydrochlorothiazide and pharmaceutically acceptable additives and is presented in the form of a two-layer tablet. Quantitative proportions of valsartan, amlodipine and hydrochlorothiazide are selected from the following: 160 mg/12.5 mg/5 mg, 160 mg/12.5 mg/10 mg, 160 mg/25 mg/10 mg, 160 mg/25 mg/5 mg and 320 mg/25 mg/10 mg. Preferentially, amlodipine is used in the form of amlodipine besylate. The two-layer tablet can contain valsartan and hydrochlorothiazide in the first layer, and amlodipine in the second layer, or valsartan in the first layer, and amlodipine and hydrochlorothiazide in the second layer. Also, there are described methods for making a two-layer tablet.

EFFECT: two-layer tablet under the invention with the fixed combination of valsartan, amlodipine and hydrochlorothiazide have the biological properties equivalent to those of a free combination of said medical agents.

17 cl, 11 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to chemical-pharmaceutical industry, and concerns a solid individual dosage forms exhibiting antistress, moderate tranquilising, nootropic, antiamnestic and antihypoxic action, containing as an active ingredient, an effective amount of 2-ethyl-6-methyl-3-pyridin-3-ole hydrochloride and pharmaceutically acceptable excipients, which contains 65.0-92.5 wt % of 2-ethyl-6-methyl-pyridin-3-ole hydrochloride, 25.6-2.5 wt % twice-substituted calcium phosphate as an excipient, 0.4-1.9 wt % of oxypropylcellulose as a binding agent and 9.0-0.6 wt % of flowing and anti-adhesion substances. Said dosage form may be presented in the form of a optionally coated marked tablet.

EFFECT: invention provides a method for making said solid individual dosage form, has high bioavailability and shelf life to 5 years.

3 cl, 9 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: composition contains an effective amount of a full length hepatocyte growth factor (flHGF) and a deletion version of hepatocyte growth factor (dHGF), or one or more polynucleotides coding said isoforms.

EFFECT: invention provides effective treatment and preventing of cardiac diseases in a subject, and also activation of endothelial cell growth in a blood vessel.

39 cl, 20 dwg, 4 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof, where Ar denotes a phenyl group substituted with piperazine or benzo[d]thiazole, with a phenyl part bonded to B, where the piperazine or benzo[d]thiazole can be unsubstituted or substituted with substitutes selected from alkyl or acetyl; B denotes -O-; R1 denotes hydrogen; R2 denotes S(O)2R4 or C(O)(CH2)n-C(O)OR5; R3 denotes halogen; R4 denotes an aryl which can be unsubstituted or substituted with substitutes selected from a group comprising halogen, alkyl, fluoroalkyl, alkoxy and trifluoromethoxy; R5 denotes hydrogen; n is a whole number from 1 to 3. The invention also relates to a method of producing said compounds and a pharmaceutical composition for treating metabolic disorders associated with insulin resistance or hyperglycaemia, based on said compounds.

EFFECT: novel compounds are obtained, which can be used in medicine to treat type 2 diabetes, obesity, glucose intolerance, dyslipidaemia, hyperinsulinaemia, atherosclerotic disease, polycystic ovary syndrome, coronary artery disease, hypertension or non-alcoholic fatty liver disease.

28 cl, 3 dwg, 4 tbl, 22 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula

,

where R denotes a substituted or unsubstituted thiazolyl group of formula or ; R4 and R5, each independently, are selected from i) hydrogen; ii) a substituted or unsubstituted C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; iii) a substituted or unsubstituted phenyl; iv) a substituted or unsubstituted heteroaryl containing 5 or 6 ring atoms and 1 or 2 heteratoms, where the heteroatoms are selected from nitrogen, oxygen, sulphur and combination thereof; or R4 and R5 can be taken together to form a saturated or unsaturated ring, having 5-7 atoms; said substitutes are independently selected from one or more groups, selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R6 denotes a group selected from i) hydrogen; ii) a substituted or unsubstituted C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; iii) a substituted or unsubstituted phenyl or iv) a substituted or unsubstituted heteroaryl containing 5 or 6 ring atoms and 1 or 2 heteroatoms, where the heteroatoms are selected from nitrogen, oxygen, sulphur and combination thereof; where said substitutes are independently selected from one or more groups selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R1 is selected from i) hydrogen; ii) C1-C6 linear or C3-C6 branched alkyl; iii) a substituted or unsubstituted phenyl or iv) a substituted or unsubstituted benzyl; where said substitutes are independently selected from one or more groups selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R2 is selected from i) C1-C6 linear or C3-C6 branched alkyl or ii) C1-C6 linear or C3-C6 branched alkoxy; R3 denotes hydrogen or C1-C4 linear or C3-C6 branched alkyl.

EFFECT: compounds of formula (I) are effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors.

20 cl, 10 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry. A matrix tablet with a trimetazidine prolonged-release base contains a core comprising 8-12% trimetazidine or its pharmaceutically acceptable salt as an active ingredient and excipients being hypromellose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide with a dissolving coating. A trimetazidine tablet is prepared by direct compression technique with film coating.

EFFECT: according to the invention, the matrix tablet formulation enables improved homogeneity and dose accuracy, provides sustained release of trimetazidine for a long period of time and maintains the required blood plasma trimetazidine concentration.

5 cl, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns a pharmaceutical composition possessing antihypoxic properties, improving coronary and cerebral circulation, improving cognitive functions, having antioxidant, antiischemic and hypolipidemic action, containing as active substances a therapeutically effective amount of 2-ethyl-6-methyl-3-oxypyridine succinate and atorvastatin, as well as pharmaceutically acceptable target additives applicable in solid dosage forms containing: a group of excipients and strength enhancing agents: lactose, dibasic calcium phosphate or microcrystalline cellulose, a group of binding substances: starch, polyvinylpyrrolidone or oxypropylmethylcellulose, a group of substances providing adequate flowability and preventing adhesion - aerosil, calcium stearate, magnesium stearate. The composition is presented in the solid dosage form such as a powder, a granule, a capsule or a tablet.

EFFECT: composition shows high bioavailability.

6 cl, 7 ex, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmacology and biology and concerns use of Trecresan as an acid phospholipase A1 modulator.

EFFECT: invention allows extending the range of acid phospholipase A1 modulators.

5 tbl, 2 ex

Transdermal plaster // 2445084

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. Substance of invention consists in the fact that a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions is produced: 6.72 wt % of hypoxene substance, 15.11 wt % of sodium metabisulphite in propylene glycol with 0.067% of sodium metabisulphite, as well as 56.0 wt % of 95% ethanol and 22.17 wt % of PVP K30. The plaster aims at the transdermal introduction of hypoxene. A plaster area is 25 cm2.

EFFECT: offered plaster used for treating and preventing chronic diseases allows avoiding the problems related to oral administration, improves patient compliance, enables prolonged maintenance of the hypoxene concentration; it is suitable for purposes of combination therapy.

6 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns a method for preparing a dosage form of a hypolipidemic, hypoglycemic agent of thioctic (α-lipoic) acid. A mixture of thioctic acid, microcrystalline cellulose and lactose is wetted with hydroxypropyl methyl cellulose in the mixture of water and ethanol; the wetted mass is mixed, dried, granulated; the granulate is added with magnesium alumomethasilicate, primojel, magnesium and/or calcium stearate, sodium stearylfumarate, aerosil and/or talc; the tablets are pressed and coated with the film Opadry II. As a result, there are produced the coated tablets containing thioctic acid 300 mg and 600 mg as the active substance.

EFFECT: prepared drug preparation provides effective daily dosage - 600 mg/day for 1 - 2 intakes; the preparation is storage stable.

2 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof, where Ar denotes a phenyl group substituted with piperazine or benzo[d]thiazole, with a phenyl part bonded to B, where the piperazine or benzo[d]thiazole can be unsubstituted or substituted with substitutes selected from alkyl or acetyl; B denotes -O-; R1 denotes hydrogen; R2 denotes S(O)2R4 or C(O)(CH2)n-C(O)OR5; R3 denotes halogen; R4 denotes an aryl which can be unsubstituted or substituted with substitutes selected from a group comprising halogen, alkyl, fluoroalkyl, alkoxy and trifluoromethoxy; R5 denotes hydrogen; n is a whole number from 1 to 3. The invention also relates to a method of producing said compounds and a pharmaceutical composition for treating metabolic disorders associated with insulin resistance or hyperglycaemia, based on said compounds.

EFFECT: novel compounds are obtained, which can be used in medicine to treat type 2 diabetes, obesity, glucose intolerance, dyslipidaemia, hyperinsulinaemia, atherosclerotic disease, polycystic ovary syndrome, coronary artery disease, hypertension or non-alcoholic fatty liver disease.

28 cl, 3 dwg, 4 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns an effect for suppressing the transplanted island damage following island transplantation by IL-6 receptor antibodies.

EFFECT: decreased transplanted island damage, increased island survival rate and corrected hyperglycemia in recipients.

17 cl, 3 ex, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and more specifically to an antidiabetic composition. What is offered is a pharmaceutical composition containing Glimepiride, poloxamer, sodium croscarmellose and other excipients - povidone, lactose monohydrate, microcrystalline cellulose, stearic acid salt and a colourant.

EFFECT: pharmaceutical composition is characterised by high therapeutic activity, satisfactory technical characteristics and shelf life of more than 2 years.

11 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely endocrinology, cardiology and can be used for treating dislipidemia. That is ensured by introducing a pharmaceutical composition containing a thiazolidinedione analogue of formula

EFFECT: introducing the compound of formula 1 having decreased binding and activation of PPAR-gamma nuclear transcription factor, enables effective treatment of dislipidemia with no adverse side effects typical for PPAR-gamma agonists.

2 dwg, 5 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology and represents using a composition containing sebacic acid and/or its derivatives selected from salts and esters for making a product for oral and enteral introduction which is applicable for: (i) treating or preventing peripheral insulin resistance, impaired glucose tolerance, diabetes, hyperglycemia and related disorders, such as nephropathy, retinopathy, cardiac and cardiovascular diseases (ii) increased glucose clearance and/or insulin responsitivity; (iii) hepatic glucose formation inhibition or (iv) reduced endogenous glucose production.

EFFECT: invention provides regulation and control of the glucose and insulin levels in healthy individuals and diabetic patients.

22 cl, 3 tbl, 5 dwg

FIELD: food industry.

SUBSTANCE: present invention relates to prevention of subsequent diseases by way of a specific nutritive composition prescription to children at an age of up to 3 years. One proposes the composition application; for production of the nutritive composition for: prevention and/or therapy of visceral adiposopathy and/or prevention and/or therapy of visceral fat mass accumulation up to an excessive quantity where the nutritive composition is prescribed for administration to a child at an age of 0 - 36 months. The composition contains a lipid, a protein components and a digestible carbohydrates component. The lipid component accounts for 35 - 55% of the total calorie content and contains less than 14.5 wt % of linoleic acid of the total fatty acids weight, the weight ratio of linoleic acid (LA) to alfa-linolenic acid (ALA) is 2 - 6. The protein component accounts for 5 - 15% of the total calorie content, the digestive carbohydrates component for 30-60% of the total calorie content. Additionally the composition may contain galactooligosaccharides, long chain polyunsaturated fatty acids (LC-PUFA) and 10-50 wt % of medium-chain fatty acids (MCFA).

EFFECT: invention allows to prevent development of disorders related to visceral adiposopathy with humans at an age over 36 months.

18 cl, 5 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula

,

where each radical R-R5 and Y assume values given in the description, or salts thereof, which have GPR40 receptor modulating action.

EFFECT: intensification of secretion of insulin or an agent for preventing or treating diabetes, and a pharmaceutical composition based on said compounds.

17 cl, 34 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a thiazole derivative of formula 1

,

as an activator of peroxisome proliferator activated receptor δ (PPARδ), or to its pharmaceutically acceptable salts.

EFFECT: production of the pharmaceutical composition for preventing and treating arteriosclerosis or hyperlipidemia, for providing higher level of high-density protein (HDP), for preventing and treating diabetes, obesity, for strengthening muscles or endurance, for improving memory or preventing and treating dementia or Alzheimer's disease or Parkinson's disease containing such thiazole derivative.

7 cl, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to conjugates of a polypeptide and an oligosaccharide or its pharmaceutically acceptable salt in which the polypeptide is conjugated to at least one oligosaccharide-spacer residues; the oligosaccharide represents a synthetic sulphated pentasaccharide residue and substantially shows affinity for antithrombine III, and the spacer shows a bond and is substantially a pharmacologically inactive flexible cross-link residue.

EFFECT: conjugates of the present invention have improved pharmacokinetic properties in comparison with appropriate unconjugated polypeptides.

13 cl, 24 dwg, 7 tbl, 28 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely physiotherapy, neurology and may be used for integrated treatment of the patients with discirculatory encephalopathy. With underlying base recovery therapy, there is prescribed magnetic infrared laser therapy generated by the "MILTA-F" apparatus of wave length 0.83 mcm, magnetic induction intensity of constant magnetic field 60 mT, exposition 0.5-2 minutes on each zone. Rge patients with atherosclerotic discirculatory encephalopathy with diffuse hemodynamic insufficiency require supravenous irradiation of ulnar vascular fascicles and sinocarotid zones in all pools every second day at irradiation frequency - 5 Hz, radiating power of light-emitting diodes - 50-90 mWt. If the given pathology is combined with arterial hypertension, additionally cervical sympathetic ganglia are irradiated at frequency - 50-80 Hz, radiating power of light-emitting diodes - 50 mWt. The therapeutic course is 10-12 daily procedures. The therapeutic course is performed three times every month.

EFFECT: method enables stabilising cerebral haemodynamics, lipid profile, arterial pressure values, improving clinical neurological semiology, functional condition of vegetative nervous system, cognitive and emotional-volitional spheres.

3 tbl, 2 ex

Up!